-
1
-
-
29144509766
-
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
-
DOI 10.1002/cncr.21536
-
Pal T, Permuth-Wey J, Betts JA, et al: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807-2816, 2005 (Pubitemid 41798292)
-
(2005)
Cancer
, vol.104
, Issue.12
, pp. 2807-2816
-
-
Pal, T.1
Permuth-Wey, J.2
Betts, J.A.3
Krischer, J.P.4
Fiorica, J.5
Arango, H.6
LaPolla, J.7
Hoffman, M.8
Martino, M.A.9
Wakeley, K.10
Wilbanks, G.11
Nicosia, S.12
Cantor, A.13
Sutphen, R.14
-
2
-
-
33845654907
-
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada
-
DOI 10.1093/jnci/djj465
-
Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706, 2006 (Pubitemid 44942707)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.23
, pp. 1694-1706
-
-
Risch, H.A.1
McLaughlin, J.R.2
Cole, D.E.C.3
Rosen, B.4
Bradley, L.5
Fan, I.6
Tang, J.7
Li, S.8
Zhang, S.9
Shaw, P.A.10
Narod, S.A.11
-
3
-
-
79955478110
-
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
-
Zhang S, Royer R, Li S, et al: Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353-357, 2011
-
(2011)
Gynecol Oncol
, vol.121
, pp. 353-357
-
-
Zhang, S.1
Royer, R.2
Li, S.3
-
4
-
-
84864026311
-
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group
-
Alsop K, Fereday S, Meldrum C, et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654-2663, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 2654-2663
-
-
Alsop, K.1
Fereday, S.2
Meldrum, C.3
-
5
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
-
(2011)
Nature
, vol.474
, pp. 609-615
-
-
-
6
-
-
79251598279
-
Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
-
Vineyard MA, Daniels MS, Urbauer DL, et al: Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol 120:229-232, 2011
-
(2011)
Gynecol Oncol
, vol.120
, pp. 229-232
-
-
Vineyard, M.A.1
Daniels, M.S.2
Urbauer, D.L.3
-
7
-
-
81155152247
-
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond
-
Banerjee S, Kaye S: PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 13:442-449, 2011
-
(2011)
Curr Oncol Rep
, vol.13
, pp. 442-449
-
-
Banerjee, S.1
Kaye, S.2
-
8
-
-
84856158117
-
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
-
Bolton KL, Chenevix-Trench G, Goh C, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382-390, 2012
-
(2012)
JAMA
, vol.307
, pp. 382-390
-
-
Bolton, K.L.1
Chenevix-Trench, G.2
Goh, C.3
-
9
-
-
84863010984
-
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
-
Kaye SB, Lubinski J, Matulonis U, et al: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372-379, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 372-379
-
-
Kaye, S.B.1
Lubinski, J.2
Matulonis, U.3
-
10
-
-
84856731422
-
Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: Lessons learned from a negative trial
-
Konstantinopoulos PA, Cannistra SA: Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: Lessons learned from a negative trial. J Clin Oncol 30:347-350, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 347-350
-
-
Konstantinopoulos, P.A.1
Cannistra, S.A.2
-
11
-
-
79955476362
-
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
-
Lacour RA, Westin SN, Meyer LA, et al: Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121:358-363, 2011
-
(2011)
Gynecol Oncol
, vol.121
, pp. 358-363
-
-
Lacour, R.A.1
Westin, S.N.2
Meyer, L.A.3
-
12
-
-
77449112281
-
Preventing future cancers by testing women with ovarian cancer for BRCA mutations
-
Kwon JS, Daniels MS, Sun CC, et al: Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 28:675-682, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 675-682
-
-
Kwon, J.S.1
Daniels, M.S.2
Sun, C.C.3
-
13
-
-
35348902805
-
Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions
-
DOI 10.1016/j.ygyno.2007.09.031, PII S0090825807007895
-
Lancaster JM, Powell CB, Kauff ND, et al: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159-162, 2007 (Pubitemid 47575743)
-
(2007)
Gynecologic Oncology
, vol.107
, Issue.2
, pp. 159-162
-
-
Lancaster, J.M.1
Bethan, P.C.2
Kauff, N.D.3
Cass, I.4
Chen, L.-M.5
Lu, K.H.6
Mutch, D.G.7
Berchuck, A.8
Karlan, B.Y.9
Herzog, T.J.10
-
14
-
-
84873742602
-
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing
-
Norquist BM, Pennington KP, Agnew KJ, et al: Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol Oncol 128:483-487, 2013
-
(2013)
Gynecol Oncol
, vol.128
, pp. 483-487
-
-
Norquist, B.M.1
Pennington, K.P.2
Agnew, K.J.3
-
15
-
-
37549072095
-
-
Genetic/Familial High Risk Assessment: Breast and Ovarian, V1
-
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Breast and Ovarian, V1.2012. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
-
(2012)
NCCN Clinical Practice Guidelines in Oncology
-
-
-
16
-
-
60849136037
-
Accuracy of the BRCAPRO model among women with bilateral breast cancer
-
Ready KJ, Vogel KJ, Atchley DP, et al: Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115:725-730, 2009
-
(2009)
Cancer
, vol.115
, pp. 725-730
-
-
Ready, K.J.1
Vogel, K.J.2
Atchley, D.P.3
-
17
-
-
0031917403
-
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
-
DOI 10.1086/301670
-
Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998 (Pubitemid 28093844)
-
(1998)
American Journal of Human Genetics
, vol.62
, Issue.1
, pp. 145-158
-
-
Parmigiani, G.1
Berry, D.A.2
Aguilar, O.3
-
19
-
-
65649118180
-
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome
-
American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, et al
-
American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, et al: ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957-966, 2009
-
(2009)
Obstet Gynecol
, vol.113
, pp. 957-966
-
-
-
20
-
-
47149086213
-
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
-
DOI 10.1136/jmg.2007.056556
-
Antoniou AC, Hardy R, Walker L, et al: Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45:425-431, 2008 (Pubitemid 351977132)
-
(2008)
Journal of Medical Genetics
, vol.45
, Issue.7
, pp. 425-431
-
-
Antoniou, A.C.1
Hardy, R.2
Walker, L.3
Evans, D.G.4
Shenton, A.5
Eeles, R.6
Shanley, S.7
Pichert, G.8
Izatt, L.9
Rose, S.10
Douglas, F.11
Eccles, D.12
Morrison, P.J.13
Scott, J.14
Zimmern, R.L.15
Easton, D.F.16
Pharoah, P.D.P.17
-
21
-
-
34848873795
-
Validity of models for predicting BRCA1 and BRCA2 mutations
-
Parmigiani G, Chen S, Iversen ES Jr, et al: Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147:441-450, 2007 (Pubitemid 351664516)
-
(2007)
Annals of Internal Medicine
, vol.147
, Issue.7
, pp. 441-450
-
-
Parmigiani, G.1
Chen, S.2
Iversen Jr., E.S.3
Friebel, T.M.4
Finkelstein, D.M.5
Anton-Culver, H.6
Ziogas, A.7
Weber, B.L.8
Eisen, A.9
Malone, K.E.10
Daling, J.R.11
Hsu, L.12
Ostrander, E.A.13
Peterson, L.E.14
Schildkraut, J.M.15
Isaacs, C.16
Corio, C.17
Leondaridis, L.18
Tomlinson, G.19
Amos, C.I.20
Strong, L.C.21
Berry, D.A.22
Weitzel, J.N.23
Sand, S.24
Dutson, D.25
Kerber, R.26
Peshkin, B.N.27
Euhus, D.M.28
more..
-
22
-
-
35648963187
-
BRCA1 and BRCA2 genetic testing in hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model
-
DOI 10.1200/JCO.2006.10.4703
-
Vogel KJ, Atchley DP, Erlichman J, et al: BRCA1 and BRCA2 genetic testing in Hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25:4635-4641, 2007 (Pubitemid 350035324)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.29
, pp. 4635-4641
-
-
Vogel, K.J.1
Atchley, D.P.2
Erlichman, J.3
Broglio, K.R.4
Ready, K.J.5
Valero, V.6
Amos, C.I.7
Hortobagyi, G.N.8
Lu, K.H.9
Arun, B.10
-
23
-
-
33646815890
-
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
-
Antoniou AC, Durocher F, Smith P, et al: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8:R3, 2006
-
(2006)
Breast Cancer Res
, vol.8
-
-
Antoniou, A.C.1
Durocher, F.2
Smith, P.3
-
24
-
-
66649102437
-
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: Findings from the Northern California Breast Cancer Family Registry
-
Kurian AW, Gong GD, John EM, et al: Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: Findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 18:1084-1091, 2009
-
(2009)
Cancer Epidemiol Biomarkers Prev
, vol.18
, pp. 1084-1091
-
-
Kurian, A.W.1
Gong, G.D.2
John, E.M.3
-
25
-
-
84880298290
-
Keeping it simple: Genetics referrals for all invasive serous ovarian cancers
-
Demsky R, McCuaig J, Maganti M, et al: Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. Gynecol Oncol 130:329-333, 2013
-
(2013)
Gynecol Oncol
, vol.130
, pp. 329-333
-
-
Demsky, R.1
McCuaig, J.2
Maganti, M.3
-
26
-
-
48949119472
-
Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
-
Tai YC, Chen S, Parmigiani G, et al: Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res 10:401, 2008
-
(2008)
Breast Cancer Res
, vol.10
, pp. 401
-
-
Tai, Y.C.1
Chen, S.2
Parmigiani, G.3
-
27
-
-
78149477590
-
Incorporating tumour pathology information into breast cancer risk prediction algorithms
-
Mavaddat N, Rebbeck TR, Lakhani SR, et al: Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 12:R28, 2010
-
(2010)
Breast Cancer Res
, vol.12
-
-
Mavaddat, N.1
Rebbeck, T.R.2
Lakhani, S.R.3
-
28
-
-
52049087559
-
What women with ovarian cancer think and know about genetic testing
-
Lacour RA, Daniels MS, Westin SN, et al: What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111:132-136, 2008
-
(2008)
Gynecol Oncol
, vol.111
, pp. 132-136
-
-
Lacour, R.A.1
Daniels, M.S.2
Westin, S.N.3
-
29
-
-
83055184366
-
There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer
-
Meiser B, Gleeson M, Kasparian N, et al: There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. Gynecol Oncol 124:153-157, 2012
-
(2012)
Gynecol Oncol
, vol.124
, pp. 153-157
-
-
Meiser, B.1
Gleeson, M.2
Kasparian, N.3
|